May 13, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing new adverse reaction risks for four drugs including Shionogi’s novel flu drug Xofluza (baloxavir marboxil) for shock and anaphylaxis - a move that is likely to result in label changes -...read more